Advertisement

Advertisement
Colorectal Cancer

Primary Surgery Outcomes in MRI-Based ‘Good-Prognosis’ Rectal Cancer

In a Canadian phase II trial reported in JAMA Oncology, Kennedy et al found a low rate of positive circumferential resection margins after primary surgery in patients with rectal cancer considered to have a ‘good prognosis’ based on magnetic resonance imaging (MRI) criteria.  

Multiple Myeloma

Patient-Reported Outcomes With Salvage Autologous Stem Cell Transplantation vs Nontransplantation in Relapsed Multiple Myeloma

In an analysis of the phase III UK Myeloma X trial reported in the Journal of Clinical Oncology, Ahmedzai et al found that patient-reported outcomes tended to be worse with salvage autologous stem cell transplantation (ASCT) vs nontransplantation consolidation in relapsed multiple myeloma. The trial, reported several years ago, showed that salvage ASCT was associated with improved time to progression, progression-free survival, and overall survival.

Issues in Oncology

10 Patient-Centered Principles for More Conservative Cancer Diagnosis

Although diagnostic errors date back to antiquity, in recent years, they have begun to receive attention as an important patient safety issue. This culminated in the National Academy of Medicine’s 2015 landmark report, which concluded that most people in the United States would experience at least one diagnostic error in their lifetime.1 Diagnostic errors are the leading cause of medical malpractice claims, and cancer is the most frequently missed or delayed diagnosis.


Advertisement
Breast Cancer

Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents

New agents for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. Although there are many controversies in breast cancer treatment, virtually none are over the first- and second-line treatments of advanced HER2-positive breast cancer. “However, in third line and beyond, where there are many different treatment options, is—to quote Dr. William Gradishar—the ‘wild, wild West,’” she said. “Right now, the main paradigm is to continue HER2-targeted therapy, but you can swap out the agent and can swap out its partner.”

Prostate Cancer

Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets

In contrast with melanoma, lung cancer, and kidney cancer, immune checkpoint inhibitor therapy has been disappointing in prostate cancer thus far. Because of success in treating other tumor types, interest remains high in exploring the effect of immunotherapy with checkpoint inhibition in prostate cancer, even though it is considered a tumor with an immunologically “cold” microenvironment.

Advertisement




More Top Stories

Lung Cancer

Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment

Warner K. Huh, MD, New President of Society of Gynecologic Oncology

WARNER K. HUH, MD, began his 1-year term as the 51st President of the Society of Gynecologic Oncology (SGO) at the conclusion of the Society’s 50th Annual Meeting on Women’s Cancer. Dr. Huh will preside over the 2020 SGO Annual Meeting on Women’s Cancer scheduled for March 28–31, 2020, in...

Advertisement

KEYNOTE-042: Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic NSCLC With PD-L1 Expression ≥ 1%

As reported in The Lancet by Mok et al, the KEYNOTE-042 trial has shown an improvement in overall survival with pembrolizumab vs standard chemotherapy in previously untreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) without a sensitizing EGFR mutation or ...

Lung Cancer

Jing Zeng, MD, on Non–Small Cell Lung Cancer: Therapeutic Implications of Proper Disease Staging

Photos From the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Arie S. Belldegrun, MD, FACS (right), receives the Keynote Award before delivering his lecture on “Progress in Cell Therapy: A Three-Decade Personal Journey.” Dr. Belldegrun is Surgical Director of the Genitourinary Oncology Department at the University of California, Los Angeles. The award was...

Warner K. Huh, MD, New President of Society of Gynecologic Oncology

WARNER K. HUH, MD, began his 1-year term as the 51st President of the Society of Gynecologic Oncology (SGO) at the conclusion of the Society’s 50th Annual Meeting on Women’s Cancer. Dr. Huh will preside over the 2020 SGO Annual Meeting on Women’s Cancer scheduled for March 28–31, 2020, in...

Front-Line Dose-Adjusted EPOCH-R vs R-CHOP in Diffuse Large B-Cell Lymphoma

As reported in the Journal of Clinical Oncology by Bartlett et al, the phase III intergroup Alliance/CALGB 50303 trial showed front-line DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) did not improve outcomes vs standard R-CHOP...

Lung Cancer

Heather A. Wakelee, MD, on Advanced Non–Small Cell Lung Cancer: State-of-the-Art Treatment for EGFR-Positive and ALK-Positive Diseases

Prostate Cancer
Immunotherapy

CheckMate 650: Nivolumab and Ipilimumab in Metastatic, Castration-Resistant Prostate Cancer

SOME PATIENTS with metastatic prostate cancer may respond to a combination of immune checkpoint inhibitors after treatment with hormonal therapy and chemotherapy is not successful, according to early results from the phase II CheckMate 650 trial. Principal Investigator Padmanee Sharma, MD, PhD,...

Advertisement

FDA Pipeline: Designations for Myelodysplastic Syndromes, Triple-Negative Breast Cancer, AML, and EBV-Associated Cancers

Over the past week, the U.S. Food and Drug Administration (FDA) granted several Fast Track and Orphan Drug designations to treatments for myelodysplastic syndromes, triple-negative breast cancer, acute myeloid leukemia (AML), and Epstein-Barr virus (EBV)-associated cancers. Fast Track Designation...